Testing Epclusa in heart transplant patients receiving hearts from hepatitis C donors
Tests Epclusa in adults receiving hearts from hepatitis C-positive donors.
Key facts
- Who runs it
- Baylor Research Institute
- Where
- Dallas, Durham, and Los Angeles, United StatesSee the 3 sites
- Trial code
- Registry title
- Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 15 people, planned
- Started
- 20 Mar 2018
- Expected to end
- 30 Dec 2026
- Type of study
- Interventional
- Treatments tested
- Epclusa
- Record updated
- 22 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults on the waiting list for a heart transplant alone. They will receive a heart from a donor with hepatitis C and be treated with sofosbuvir/velpatasvir (Epclusa).
- Age
- 18 Years to 90 Years
- Sex
- All sexes can join.
- Disease stage
- Listed for an isolated heart transplant (heart only, no other organ).
- Earlier treatment
- Cannot have had a solid organ transplant before. Cannot have had or be going to have immune desensitization therapy.
- Biomarker or test result
- Hepatitis C negative on blood test. If hepatitis C positive before, the infection must be cleared, with 2 negative PCR tests and the last antiviral dose at least 12 weeks ago.
Main reasons for not taking part
- Listed for more than one organ transplant at once
- Liver disease, such as cirrhosis, portal hypertension or hepatitis B
- Pregnancy
- HIV infection, or kidney disease needing dialysis
- Unwilling to tell sexual partner(s) about taking part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Willing and capable of providing written informed consent
- Age ≥ 18 years
- Listed for isolated orthotopic heart transplant
- HCV seronegative (or, if HCV seropositive, then subject must be PCR negative on at least 2 draws consistent with a spontaneously cleared or fully-treated and cleared prior infection; in this case last anti-HCV antiviral dose must be ≥12 weeks ago and 2 negative titers ≥12 weeks after completion of the antiviral regimen)
Who cannot take part
- Listed for combined organ transplant
- History of prior solid organ transplant
- Patients who have undergone or who will undergo immune desensitization therapy
- History of HIV infection
- Any of the following liver disease states, including:; History of HCV viremia detectable by either HCV qualitative or quantitative PCR unless deemed cured (SVR-12),; Hepatitis B surface Ag positive(unless clinically determined to be previously negative and acutely positive due to vaccination with recombinant surface antigen) or detectable hepatitis B DNA,; Cirrhosis, as indicated by liver biopsy,; Portal hypertension as indicated by a hepatic venous pressure gradient > 5 mm Hg and/or the presence of esophageal varices e.) ALT and AST > 3x ULN unless adjudicated to be from a non-hepatic cardiac or skeletal muscle source,
- History of severe renal disease currently requiring dialysis. Chronic kidney disease with creatinine clearance <30 ml/min/1.73m2 (by MDRD method) at screening or on last two consecutive measurements before acceptance of transplant organ offer
- Pregnant individuals
- Prospective-positive cross-match or predicted positive cross-match
- Patients unwilling to notify their sexual partner(s) of participation in this trial
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Where in United States
- Baylor University Medical CenterDallas, United StatesContact: Aayla Jamil, MBBS MPHTaking people
- Duke University Medical CenterDurham, United StatesContact: Aayla Jamil, MBBS MPHNo longer taking part
- Cedars-Sinai Medical CenterLos Angeles, United StatesContact: Sean SanaTaking people
About the trial
What the trial wants to find out
This phase II, multi-center, open-label study will evaluate the safety and efficacy of utilizing HCV-positive donors for heart transplant in HCV-negative recipients treated with sofosbuvir 400 mg / velpatasvir 100 mg (Epclusa®).
The group in the trial
- TreatmentTreatment being tested
Epclusa® will be started within 14 days of quantifiable viremia and continued for 12 weeks. Within 24 hours prior to first-dose of treatment, HCV genotype will be sent from transplant recipient.
Treatment: Epclusa
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients
- Plain-language title
- Testing Epclusa in heart transplant patients receiving hearts from hepatitis C donorsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT03383419, who can take part
- Record updated
- 22 January 2026